Company intelligence / Profile preview

Botanix Pharmaceuticals

Perth, Western Australia, Australiabotanixpharma.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

Sofdra™ (sofpironium bromide gel) was recently approved by the US FDA for primary axillary hyperhidrosis after demonstrating statistical significance on all endpoints with a favorable safety profile in Phase III trials. Other pipeline assets have shown positive results in Phase I/II studies, particularly BTX1702 for rosacea and BTX1801 for antimicrobial use.[1][6][10]

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small molecules (notably synthetic cannabinoids and sofpironium bromide)[7][10]
Industry: Biotech

Drug pipeline

8 assets

sofpironium

Approved

7 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships publicly disclosed as of May 2025; exclusive license to Permetrex® technology.[7]

Beyond the preview

Go deeper on Botanix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Botanix Pharmaceuticals.

Explore the full profile